{"transactions":[{"id":1303816,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-01-14T16:15:24.000Z","date":"2025-01-10","kind":"grant","planned":false,"acquired":true,"shares":14814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares of common stock that vest pro rata on a monthly basis for 12 months commencing on February 10, 2025."}],"balance_after":1080062,"source":{"system":"sec-edgar","filing":"0001493152-25-002148","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315225002148/ownership.xml","form_type":"4"}},{"id":1463869,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-07-02T18:47:13.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":33784,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024."}],"balance_after":1065248,"source":{"system":"sec-edgar","filing":"0001493152-24-026092","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224026092/ownership.xml","form_type":"4"}},{"id":1479596,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-06-14T20:46:00.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":8296,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares of common stock, par value $0.007 per share, that vest immediately."}],"balance_after":1031464,"source":{"system":"sec-edgar","filing":"0001493152-24-023994","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224023994/ownership.xml","form_type":"4"}},{"id":1536375,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-24T16:00:20.000Z","date":"2024-04-03","kind":"exercise","planned":false,"acquired":false,"shares":64848,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vested in 7 equal monthly installments beginning on April 28, 2014."}],"balance_after":0,"derivative":{"exercise_price":1.16,"expiration_date":"2024-04-28","underlying":"Common Stock","underlying_shares":64848},"source":{"system":"sec-edgar","filing":"0001493152-24-015789","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224015789/ownership.xml","form_type":"4"}},{"id":1536374,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-24T16:00:20.000Z","date":"2024-04-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":33438,"price":2.24,"value":74901.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares withheld to cover the exercise price of the options exercised."}],"balance_after":1023168,"source":{"system":"sec-edgar","filing":"0001493152-24-015789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224015789/ownership.xml","form_type":"4"}},{"id":1536373,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-04-24T16:00:20.000Z","date":"2024-04-03","kind":"exercise","planned":false,"acquired":true,"shares":64848,"price":1.16,"value":75223.68,"ownership":{"direct":true},"balance_after":1056606,"source":{"system":"sec-edgar","filing":"0001493152-24-015789","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224015789/ownership.xml","form_type":"4"}},{"id":1557727,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-03-29T16:53:35.000Z","date":"2024-02-16","kind":"grant","planned":false,"acquired":true,"shares":39474,"price":1.52,"value":60000.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which shares will vest in full on February 16, 2027, the third anniversary of the grant date."}],"balance_after":991758,"source":{"system":"sec-edgar","filing":"0001493152-24-012014","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224012014/ownership.xml","form_type":"4"}},{"id":1662321,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-02T16:20:17.000Z","date":"2024-01-31","kind":"grant","planned":false,"acquired":true,"shares":11943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Grant of restricted shares, which shares will vest pro rata on a monthly basis for 12 months commencing on February 29, 2024."}],"balance_after":952284,"source":{"system":"sec-edgar","filing":"0001493152-24-004760","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224004760/ownership.xml","form_type":"4"}},{"id":1672307,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-01-24T20:52:56.000Z","date":"2024-01-01","kind":"grant","planned":false,"acquired":true,"shares":12668,"price":1.48,"value":18748.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a grant from the Issuer to Mr. Girgenti of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year"}],"balance_after":940341,"source":{"system":"sec-edgar","filing":"0001493152-24-003691","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224003691/ownership.xml","form_type":"4"}},{"id":1672306,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-01-24T20:52:56.000Z","date":"2023-10-01","kind":"grant","planned":false,"acquired":true,"shares":11867,"price":1.58,"value":18749.86,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant from the Issuer to Mr. Girgenti of 11,867 restricted shares of Common Stock, on October 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year."}],"balance_after":927673,"source":{"system":"sec-edgar","filing":"0001493152-24-003691","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315224003691/ownership.xml","form_type":"4"}},{"id":1810198,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-08-11T16:00:34.000Z","date":"2023-08-09","kind":"grant","planned":false,"acquired":true,"shares":26315,"price":2.28,"value":59998.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents a grant from the Issuer to Mr. Girgenti of 26,315 shares of Common Stock on August 9, 2023 pursuant to the terms of his employment agreement."}],"balance_after":915806,"source":{"system":"sec-edgar","filing":"0001493152-23-027815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315223027815/ownership.xml","form_type":"4"}},{"id":1810197,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-08-11T16:00:34.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":10245,"price":1.83,"value":18748.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a grant from the Issuer to Mr. Girgenti of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year."}],"balance_after":889491,"source":{"system":"sec-edgar","filing":"0001493152-23-027815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315223027815/ownership.xml","form_type":"4"}},{"id":1810196,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-08-11T16:00:34.000Z","date":"2023-04-15","kind":"grant","planned":false,"acquired":true,"shares":9920,"price":1.89,"value":18748.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a grant from the Issuer to Mr. Girgenti of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Mr. Girgenti continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year."}],"balance_after":879246,"source":{"system":"sec-edgar","filing":"0001493152-23-027815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315223027815/ownership.xml","form_type":"4"}},{"id":1810195,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-08-11T16:00:34.000Z","date":"2023-01-01","kind":"grant","planned":false,"acquired":true,"shares":8227,"price":2.28,"value":18757.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant from bioAffinity Technologies, Inc. (the \"Issuer\") to Mr. Girgenti of 8,227 restricted shares of common stock, par value $0.007 (the \"Common Stock\"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year."}],"balance_after":869326,"source":{"system":"sec-edgar","filing":"0001493152-23-027815","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315223027815/ownership.xml","form_type":"4"}},{"id":1834277,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-07-06T16:15:18.000Z","date":"2023-07-01","kind":"grant","planned":false,"acquired":true,"shares":10245,"price":1.83,"value":18748.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents a grant from the Issuer to Mr. Girgenti of 10,245 restricted shares of Common Stock, on July 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year."}],"balance_after":889491,"source":{"system":"sec-edgar","filing":"0001493152-23-023821","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315223023821/ownership.xml","form_type":"4"}},{"id":1834276,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-07-06T16:15:18.000Z","date":"2023-04-15","kind":"grant","planned":false,"acquired":true,"shares":9920,"price":1.89,"value":18748.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents a grant from the Issuer to Mr. Girgenti of 9,920 restricted shares of Common Stock on April 15, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest one-third on the date of grant, one-third on May 1, 2023 and the remaining shares on June 1, 2023, provided Mr. Girgenti continues to serve as a director, and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year."}],"balance_after":879246,"source":{"system":"sec-edgar","filing":"0001493152-23-023821","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315223023821/ownership.xml","form_type":"4"}},{"id":1834275,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-07-06T16:15:18.000Z","date":"2023-01-01","kind":"grant","planned":false,"acquired":true,"shares":8227,"price":2.28,"value":18757.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a grant from bioAffinity Technologies, Inc. (the \"Issuer\") to Mr. Girgenti of 8,227 restricted shares of common stock, par value $0.007 (the \"Common Stock\"), on January 1, 2023 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year."}],"balance_after":869326,"source":{"system":"sec-edgar","filing":"0001493152-23-023821","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315223023821/ownership.xml","form_type":"4"}},{"id":2122561,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-07-20","kind":"purchase","acquired":true,"shares":2380,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F24","text":"Represents a right to purchase 2,380 shares of Common Stock underlying a warrant at an exercise price of $5.25 per share. The warrant was issued to the Trust on July 20, 2022 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Note issued to the Trust under the Note Purchase Agreement from August 31, 2022 to October 31, 2022.."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by the Cranye Girgenti Testamentary Trust (the \"Trust\"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":2380,"derivative":{"exercise_price":5.25,"exercise_date":"2022-07-20","expiration_date":"2027-07-20","underlying":"Common Stock","underlying_shares":2380},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":39,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122560,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-07-20","kind":"grant","acquired":true,"shares":123811,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F23","text":"Represents a right to purchase 123,811 shares of Common Stock underlying 10 warrants at an exercise price of $5.25 per share. The warrants were issued to Mr. Girgenti on July 20, 2022 as consideration for his agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from August 31, 2022 to October 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F23","text":"Represents a right to purchase 123,811 shares of Common Stock underlying 10 warrants at an exercise price of $5.25 per share. The warrants were issued to Mr. Girgenti on July 20, 2022 as consideration for his agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from August 31, 2022 to October 31, 2022."}],"balance_after":123811,"derivative":{"exercise_price":5.25,"exercise_date":"2022-07-20","expiration_date":"2027-07-20","underlying":"Common Stock","underlying_shares":123811},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":38,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122559,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"grant","acquired":true,"shares":35714,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F22","text":"Represents a right to purchase 35,714 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Girgenti on August 11, 2022 as consideration for funds Mr. Girgenti paid to the Issuer for his unsecured Note, dated August 11, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F22","text":"Represents a right to purchase 35,714 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Girgenti on August 11, 2022 as consideration for funds Mr. Girgenti paid to the Issuer for his unsecured Note, dated August 11, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"Represents a right to purchase 35,714 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to Mr. Girgenti on August 11, 2022 as consideration for funds Mr. Girgenti paid to the Issuer for his unsecured Note, dated August 11, 2022."}],"balance_after":35714,"derivative":{"exercise_price":6.125,"exercise_date":"2022-09-06","expiration_date":"2027-08-11","underlying":"Common Stock","underlying_shares":35714},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":37,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122558,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"grant","acquired":true,"shares":87605,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F21","text":"Represents a right to purchase an aggregate of 87,605 shares of Common Stock underlying six warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on December 2, 2021 as consideration for his agreement to enter into amendments to extend the maturity dates of certain of his unsecured Notes to May 31, 2022."},{"field":"shares","element":"transactionShares","label":"F21","text":"Represents a right to purchase an aggregate of 87,605 shares of Common Stock underlying six warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on December 2, 2021 as consideration for his agreement to enter into amendments to extend the maturity dates of certain of his unsecured Notes to May 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"Represents a right to purchase an aggregate of 87,605 shares of Common Stock underlying six warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on December 2, 2021 as consideration for his agreement to enter into amendments to extend the maturity dates of certain of his unsecured Notes to May 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F21","text":"Represents a right to purchase an aggregate of 87,605 shares of Common Stock underlying six warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on December 2, 2021 as consideration for his agreement to enter into amendments to extend the maturity dates of certain of his unsecured Notes to May 31, 2022."}],"balance_after":87605,"derivative":{"exercise_price":6.125,"exercise_date":"2022-09-06","expiration_date":"2026-12-02","underlying":"Common Stock","underlying_shares":87605},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":36,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122557,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"purchase","acquired":true,"shares":5952,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F20","text":"Represents a right to purchase 5,952 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to the Trust on August 25, 2021 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Note issued to the Trust under the Note Purchase Agreement from December 31, 2021 to May 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F20","text":"Represents a right to purchase 5,952 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to the Trust on August 25, 2021 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Note issued to the Trust under the Note Purchase Agreement from December 31, 2021 to May 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"Represents a right to purchase 5,952 shares of Common Stock underlying a warrant that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrant was issued to the Trust on August 25, 2021 as consideration for the Trust's agreement to enter into an amendment to the Note Purchase Agreement to extend the maturity date of the Note issued to the Trust under the Note Purchase Agreement from December 31, 2021 to May 31, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by the Cranye Girgenti Testamentary Trust (the \"Trust\"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":5952,"derivative":{"exercise_price":6.125,"exercise_date":"2022-09-06","expiration_date":"2026-08-25","underlying":"Common Stock","underlying_shares":5952},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122556,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"grant","acquired":true,"shares":221933,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F19","text":"Represents a right to purchase an aggregate of 221,933 shares of Common Stock underlying four warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on August 25, 2021 as consideration for his agreement to enter into an amendment to that certain Secured Convertible Note Purchase Agreement, dated December 21, 2018, as amended (the \"Note Purchase Agreement\") to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from December 31, 2021 to May 31, 2022."},{"field":"shares","element":"transactionShares","label":"F19","text":"Represents a right to purchase an aggregate of 221,933 shares of Common Stock underlying four warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on August 25, 2021 as consideration for his agreement to enter into an amendment to that certain Secured Convertible Note Purchase Agreement, dated December 21, 2018, as amended (the \"Note Purchase Agreement\") to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from December 31, 2021 to May 31, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Represents a right to purchase an aggregate of 221,933 shares of Common Stock underlying four warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on August 25, 2021 as consideration for his agreement to enter into an amendment to that certain Secured Convertible Note Purchase Agreement, dated December 21, 2018, as amended (the \"Note Purchase Agreement\") to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from December 31, 2021 to May 31, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F19","text":"Represents a right to purchase an aggregate of 221,933 shares of Common Stock underlying four warrants that became initially exercisable in connection with the IPO Closing on September 6, 2022 at an exercise price equal to the IPO price of $6.125 per share. The warrants were issued to Mr. Girgenti on August 25, 2021 as consideration for his agreement to enter into an amendment to that certain Secured Convertible Note Purchase Agreement, dated December 21, 2018, as amended (the \"Note Purchase Agreement\") to extend the maturity date of the Notes issued to him under the Note Purchase Agreement from December 31, 2021 to May 31, 2022."}],"balance_after":221933,"derivative":{"exercise_price":6.125,"exercise_date":"2022-09-06","expiration_date":"2026-08-25","underlying":"Common Stock","underlying_shares":221933},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122555,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Non-tradeable Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"shares":40916,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F18","text":"The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share."}],"balance_after":40916,"derivative":{"exercise_price":7.656,"exercise_date":"2022-08-31","expiration_date":"2027-08-31","underlying":"Common Stock","underlying_shares":40916},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122554,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Warrants (right to buy)","published_at":"2022-11-08T06:11:36.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"shares":40916,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F18","text":"The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share."}],"balance_after":40916,"derivative":{"exercise_price":7.35,"exercise_date":"2022-08-31","expiration_date":"2027-08-31","underlying":"Common Stock","underlying_shares":40916},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122553,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"shares":9091,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F17","text":"In connection with the IPO Closing on September 6, 2022, the 9,091 shares of Series A Preferred Stock owned by the Trust automatically converted at the then-effective 1-for-7 conversion rate into 1,298 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"In connection with the IPO Closing on September 6, 2022, the 9,091 shares of Series A Preferred Stock owned by the Trust automatically converted at the then-effective 1-for-7 conversion rate into 1,298 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F17","text":"In connection with the IPO Closing on September 6, 2022, the 9,091 shares of Series A Preferred Stock owned by the Trust automatically converted at the then-effective 1-for-7 conversion rate into 1,298 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by the Cranye Girgenti Testamentary Trust (the \"Trust\"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":7.7,"underlying":"Common Stock","underlying_shares":1298},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122552,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Series A Convertible Preferred Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"shares":972957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F16","text":"In connection with the IPO Closing on September 6, 2022, the 972,957 shares of Series A Preferred Stock owned by Mr. Girgenti automatically converted at the then-effective 1-for-7 conversion rate into 138,993 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"In connection with the IPO Closing on September 6, 2022, the 972,957 shares of Series A Preferred Stock owned by Mr. Girgenti automatically converted at the then-effective 1-for-7 conversion rate into 138,993 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F16","text":"In connection with the IPO Closing on September 6, 2022, the 972,957 shares of Series A Preferred Stock owned by Mr. Girgenti automatically converted at the then-effective 1-for-7 conversion rate into 138,993 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."}],"balance_after":0,"derivative":{"exercise_price":3.6,"underlying":"Common Stock","underlying_shares":138993},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122551,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":150641.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F15","text":"In connection with the IPO Closing on September 6, 2022, the $150,641.10 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated August 11, 2022, automatically converted into 35,866 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"In connection with the IPO Closing on September 6, 2022, the $150,641.10 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated August 11, 2022, automatically converted into 35,866 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":35866},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122550,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":65654.79,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F14","text":"In connection with the IPO Closing on September 6, 2022, the $65,654.79 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated July 3, 2021, automatically converted into 15,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"In connection with the IPO Closing on September 6, 2022, the $65,654.79 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated July 3, 2021, automatically converted into 15,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-12-31","underlying":"Common Stock","underlying_shares":15632},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122549,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":164958.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F13","text":"In connection with the IPO Closing on September 6, 2022, the $164,958.90 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated June 8, 2021, automatically converted into 39,275 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"In connection with the IPO Closing on September 6, 2022, the $164,958.90 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated June 8, 2021, automatically converted into 39,275 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":39275},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122548,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":44655.34,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F12","text":"In connection with the IPO Closing on September 6, 2022, the $44,655.34 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 24, 2021, automatically converted into 10,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"In connection with the IPO Closing on September 6, 2022, the $44,655.34 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 24, 2021, automatically converted into 10,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":10632},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122547,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":55972.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F11","text":"In connection with the IPO Closing on September 6, 2022, the $55,972.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 10, 2021, automatically converted into 13,326 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"In connection with the IPO Closing on September 6, 2022, the $55,972.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 10, 2021, automatically converted into 13,326 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":13326},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122546,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":11317.26,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F10","text":"In connection with the IPO Closing on September 6, 2022, the $11,317.26 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated January 13, 2021, automatically converted into 2,694 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"In connection with the IPO Closing on September 6, 2022, the $11,317.26 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated January 13, 2021, automatically converted into 2,694 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":2694},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122545,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":20633.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"In connection with the IPO Closing on September 6, 2022, the $20,633.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 26, 2020, automatically converted into 4,912 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"In connection with the IPO Closing on September 6, 2022, the $20,633.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 26, 2020, automatically converted into 4,912 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":4912},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122544,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Unsecured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":114991.78,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"In connection with the IPO Closing on September 6, 2022, the $114,991.78 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 22, 2020, automatically converted into 27,378 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"In connection with the IPO Closing on September 6, 2022, the $114,991.78 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 22, 2020, automatically converted into 27,378 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":27378},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122543,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Secured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":246947.95,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"In connection with the IPO Closing on September 6, 2022, the $246,947.95 of outstanding principal and accrued but unpaid interest of this secured Note, dated October 1, 2019, automatically converted into 58,797 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"In connection with the IPO Closing on September 6, 2022, the $246,947.95 of outstanding principal and accrued but unpaid interest of this secured Note, dated October 1, 2019, automatically converted into 58,797 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":58797},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122542,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Secured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":248394.52,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"In connection with the IPO Closing on September 6, 2022, the $248,394.52 of outstanding principal and accrued but unpaid interest of this secured Note, dated August 29, 2019, automatically converted into 59,141 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"In connection with the IPO Closing on September 6, 2022, the $248,394.52 of outstanding principal and accrued but unpaid interest of this secured Note, dated August 29, 2019, automatically converted into 59,141 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":59141},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122541,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Secured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":32161.64,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured Note, dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured Note, dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122540,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Secured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":657731.96,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"In connection with the IPO Closing on September 6, 2022, the $657,731.96 of outstanding principal and accrued but unpaid interest of this secured Note, dated December 21, 2018, automatically converted into 156,602 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"In connection with the IPO Closing on September 6, 2022, the $657,731.96 of outstanding principal and accrued but unpaid interest of this secured Note, dated December 21, 2018, automatically converted into 156,602 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":156602},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122539,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Secured Convertible Promissory Note","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":false,"price":0,"reported_value":32161.64,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a \"Note\"), dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a \"Note\"), dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by the Cranye Girgenti Testamentary Trust (the \"Trust\"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":4.2,"exercise_date":"2022-09-06","expiration_date":"2022-10-31","underlying":"Common Stock","underlying_shares":7657},"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122538,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-08-31","kind":"purchase","acquired":true,"shares":40916,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The reported securities are included within 40,916 Units purchased by Mr. Girgenti for $6.125 per Unit in the Issuer's IPO. Each Unit consists of one share of Common Stock, one tradeable warrant to purchase one share of Common Stock at an exercise price of $7.35 per share, and one five-year non-tradeable warrant to purchase one share of Common Stock at an exercise price of $7.656 per share."}],"balance_after":861099,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122537,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":1298,"price":7.7,"value":9994.6,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F17","text":"In connection with the IPO Closing on September 6, 2022, the 9,091 shares of Series A Preferred Stock owned by the Trust automatically converted at the then-effective 1-for-7 conversion rate into 1,298 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"In connection with the IPO Closing on September 6, 2022, the 9,091 shares of Series A Preferred Stock owned by the Trust automatically converted at the then-effective 1-for-7 conversion rate into 1,298 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by the Cranye Girgenti Testamentary Trust (the \"Trust\"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":8955,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122536,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":138993,"price":3.6,"value":500374.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F16","text":"In connection with the IPO Closing on September 6, 2022, the 972,957 shares of Series A Preferred Stock owned by Mr. Girgenti automatically converted at the then-effective 1-for-7 conversion rate into 138,993 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"In connection with the IPO Closing on September 6, 2022, the 972,957 shares of Series A Preferred Stock owned by Mr. Girgenti automatically converted at the then-effective 1-for-7 conversion rate into 138,993 fully paid and nonassessable shares of Common Stock. The Series A Preferred Stock had no expiration date."}],"balance_after":820183,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122535,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":35866,"price":4.2,"value":150637.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F15","text":"In connection with the IPO Closing on September 6, 2022, the $150,641.10 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated August 11, 2022, automatically converted into 35,866 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"In connection with the IPO Closing on September 6, 2022, the $150,641.10 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated August 11, 2022, automatically converted into 35,866 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":681190,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122534,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":15632,"price":4.2,"value":65654.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F14","text":"In connection with the IPO Closing on September 6, 2022, the $65,654.79 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated July 3, 2021, automatically converted into 15,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"In connection with the IPO Closing on September 6, 2022, the $65,654.79 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated July 3, 2021, automatically converted into 15,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":645324,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122533,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":39275,"price":4.2,"value":164955.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F13","text":"In connection with the IPO Closing on September 6, 2022, the $164,958.90 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated June 8, 2021, automatically converted into 39,275 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"In connection with the IPO Closing on September 6, 2022, the $164,958.90 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated June 8, 2021, automatically converted into 39,275 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":629692,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122532,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":10632,"price":4.2,"value":44654.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F12","text":"In connection with the IPO Closing on September 6, 2022, the $44,655.34 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 24, 2021, automatically converted into 10,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"In connection with the IPO Closing on September 6, 2022, the $44,655.34 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 24, 2021, automatically converted into 10,632 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":590417,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122531,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":13326,"price":4.2,"value":55969.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F11","text":"In connection with the IPO Closing on September 6, 2022, the $55,972.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 10, 2021, automatically converted into 13,326 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"In connection with the IPO Closing on September 6, 2022, the $55,972.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated March 10, 2021, automatically converted into 13,326 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":579785,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122530,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":2694,"price":4.2,"value":11314.8,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F10","text":"In connection with the IPO Closing on September 6, 2022, the $11,317.26 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated January 13, 2021, automatically converted into 2,694 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"In connection with the IPO Closing on September 6, 2022, the $11,317.26 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated January 13, 2021, automatically converted into 2,694 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":566459,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122529,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":4912,"price":4.2,"value":20630.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F9","text":"In connection with the IPO Closing on September 6, 2022, the $20,633.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 26, 2020, automatically converted into 4,912 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"In connection with the IPO Closing on September 6, 2022, the $20,633.60 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 26, 2020, automatically converted into 4,912 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":563765,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122528,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":27378,"price":4.2,"value":114987.6,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F8","text":"In connection with the IPO Closing on September 6, 2022, the $114,991.78 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 22, 2020, automatically converted into 27,378 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"In connection with the IPO Closing on September 6, 2022, the $114,991.78 of outstanding principal and accrued but unpaid interest of this unsecured Note, dated October 22, 2020, automatically converted into 27,378 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":558853,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122527,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":58797,"price":4.2,"value":246947.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F7","text":"In connection with the IPO Closing on September 6, 2022, the $246,947.95 of outstanding principal and accrued but unpaid interest of this secured Note, dated October 1, 2019, automatically converted into 58,797 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"In connection with the IPO Closing on September 6, 2022, the $246,947.95 of outstanding principal and accrued but unpaid interest of this secured Note, dated October 1, 2019, automatically converted into 58,797 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":531475,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122526,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":59141,"price":4.2,"value":248392.2,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F6","text":"In connection with the IPO Closing on September 6, 2022, the $248,394.52 of outstanding principal and accrued but unpaid interest of this secured Note, dated August 29, 2019, automatically converted into 59,141 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"In connection with the IPO Closing on September 6, 2022, the $248,394.52 of outstanding principal and accrued but unpaid interest of this secured Note, dated August 29, 2019, automatically converted into 59,141 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":472678,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122525,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":7657,"price":4.2,"value":32159.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F5","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured Note, dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured Note, dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":413537,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122524,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":156602,"price":4.2,"value":657728.4,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"In connection with the IPO Closing on September 6, 2022, the $657,731.96 of outstanding principal and accrued but unpaid interest of this secured Note, dated December 21, 2018, automatically converted into 156,602 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In connection with the IPO Closing on September 6, 2022, the $657,731.96 of outstanding principal and accrued but unpaid interest of this secured Note, dated December 21, 2018, automatically converted into 156,602 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."}],"balance_after":405880,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2122523,"issuer":{"id":8368,"kind":"organization","name":"bioAffinity Technologies, Inc."},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-11-08T06:11:36.000Z","date":"2022-09-06","kind":"exercise","acquired":true,"shares":7657,"price":4.2,"value":32159.4,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The number of securities and exercise prices reported in this Form 4 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the \"Common Stock\"), of bioAffinity Technologies, Inc. (the \"Issuer\"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the \"IPO\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a \"Note\"), dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"In connection with the IPO Closing on September 6, 2022, the $32,161.64 of outstanding principal and accrued but unpaid interest of this secured convertible promissory note (a \"Note\"), dated February 7, 2019, automatically converted into 7,657 shares of Common Stock at a conversion price of $4.20 per share (on a Common Stock equivalent basis)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These securities are owned directly by the Cranye Girgenti Testamentary Trust (the \"Trust\"), and indirectly by Mr. Girgenti as co-trustee of the Trust. Mr. Girgenti disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein."}],"balance_after":7657,"source":{"system":"sec-edgar","filing":"0001493152-22-030872","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315222030872/ownership.xml","form_type":"4"}},{"id":2753266,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2021-04-08T06:32:56.000Z","date":"2021-04-01","kind":"other","acquired":true,"shares":33.333,"price":0.21,"value":6.99993,"ownership":{"direct":true},"balance_after":625449,"source":{"system":"sec-edgar","filing":"0001493152-21-008263","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315221008263/ownership.xml","form_type":"4"}},{"id":2911182,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2021-01-11T15:26:42.000Z","date":"2021-01-01","kind":"other","acquired":true,"shares":33.333,"price":0.21,"value":6.99993,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":592116,"source":{"system":"sec-edgar","filing":"0001493152-21-000737","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315221000737/ownership.xml","form_type":"4"}},{"id":3011905,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2020-10-06T17:20:16.000Z","date":"2020-10-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":558783,"source":{"system":"sec-edgar","filing":"0001493152-20-019046","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315220019046/ownership.xml","form_type":"4"}},{"id":3087715,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2020-07-07T21:37:02.000Z","date":"2020-07-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":525450,"source":{"system":"sec-edgar","filing":"0001493152-20-012775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315220012775/ownership.xml","form_type":"4"}},{"id":3180908,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2020-04-07T06:16:45.000Z","date":"2020-04-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":492117,"source":{"system":"sec-edgar","filing":"0001493152-20-005944","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315220005944/ownership.xml","form_type":"4"}},{"id":3316751,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2020-01-07T06:07:45.000Z","date":"2020-01-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":458784,"source":{"system":"sec-edgar","filing":"0001493152-20-000287","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315220000287/ownership.xml","form_type":"4"}},{"id":3395526,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2019-10-09T14:50:39.000Z","date":"2019-10-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":425451,"source":{"system":"sec-edgar","filing":"0001493152-19-015294","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315219015294/ownership.xml","form_type":"4"}},{"id":3472100,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2019-07-02T16:41:35.000Z","date":"2019-07-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":392118,"source":{"system":"sec-edgar","filing":"0001493152-19-010161","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315219010161/ownership.xml","form_type":"4"}},{"id":3565928,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2019-04-03T15:25:52.000Z","date":"2019-04-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":358785,"source":{"system":"sec-edgar","filing":"0001493152-19-004810","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315219004810/ownership.xml","form_type":"4"}},{"id":3700947,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2019-01-08T13:51:09.000Z","date":"2019-01-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":325452,"source":{"system":"sec-edgar","filing":"0001493152-19-000307","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315219000307/ownership.xml","form_type":"4"}},{"id":3785332,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2018-10-23T09:29:38.000Z","date":"2018-10-01","kind":"other","acquired":true,"shares":24138,"price":0.29,"value":7000.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":292119,"source":{"system":"sec-edgar","filing":"0001493152-18-014775","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315218014775/ownership.xml","form_type":"4"}},{"id":3870608,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2018-07-10T06:03:42.000Z","date":"2018-07-01","kind":"other","acquired":true,"shares":21212,"price":0.33,"value":6999.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":267981,"source":{"system":"sec-edgar","filing":"0001493152-18-009840","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315218009840/ownership.xml","form_type":"4"}},{"id":3970408,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2018-04-04T13:11:46.000Z","date":"2018-04-01","kind":"other","acquired":true,"shares":14583,"price":0.48,"value":6999.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":246769,"source":{"system":"sec-edgar","filing":"0001493152-18-004740","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315218004740/form4.xml","form_type":"4"}},{"id":4113446,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2018-01-03T12:45:55.000Z","date":"2018-01-01","kind":"other","acquired":true,"shares":18919,"price":0.37,"value":7000.03,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":232186,"source":{"system":"sec-edgar","filing":"0001493152-18-000081","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315218000081/form4.xml","form_type":"4"}},{"id":4190343,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock par value $0.0001","published_at":"2017-10-06T15:15:18.000Z","date":"2017-10-01","kind":"other","acquired":true,"shares":25000,"price":0.28,"value":7000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":213267,"source":{"system":"sec-edgar","filing":"0001493152-17-011379","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315217011379/form4.xml","form_type":"4"}},{"id":4253381,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock pure value $0.0001","published_at":"2017-07-21T15:37:12.000Z","date":"2017-07-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes an adjustment of 7,387 shares based upon a calculation error in the reporting person's report as of October 31, 2016."}],"balance_after":188267,"source":{"system":"sec-edgar","filing":"0001493152-17-008079","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315217008079/form4.xml","form_type":"4"}},{"id":4356997,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock pure value $0.0001","published_at":"2017-04-06T15:55:10.000Z","date":"2017-04-01","kind":"other","acquired":true,"shares":33333,"price":0.21,"value":6999.93,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":147547,"source":{"system":"sec-edgar","filing":"0001493152-17-003586","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315217003586/form4.xml","form_type":"4"}},{"id":4491264,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Vycor Medical Inc. Common Stock pure value $0.0001","published_at":"2017-01-13T14:03:23.000Z","date":"2017-01-01","kind":"other","acquired":true,"shares":21212,"price":0.33,"value":6999.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a quarterly grant of shares as compensation for services as a director of the issuer pursuant to the Directors' Deferred compensation plan of the Issuer, however, the Reporting person has elected to defer receipt of the shares until January 15th of the year following his termination of services as a director."}],"balance_after":114214,"source":{"system":"sec-edgar","filing":"0001493152-17-000450","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000149315217000450/form4.xml","form_type":"4"}},{"id":4582771,"issuer":{"id":8497,"kind":"organization","name":"VYCOR MEDICAL INC"},"owners":[{"id":84166,"kind":"person","name":"GIRGENTI STEVEN","position":1,"cik":"0001055530","reported_name":"GIRGENTI STEVEN","relationship":{"director":true}}],"security":"Vycor Medical Inc. Common Stock pure value $0.0001","published_at":"2016-10-07T13:57:25.000Z","date":"2016-10-01","kind":"other","acquired":true,"shares":20588,"price":0.34,"value":6999.92,"ownership":{"direct":true},"balance_after":93002,"source":{"system":"sec-edgar","filing":"0001354488-16-008370","document":"issuerdirect_section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055530/000135448816008370/issuerdirect_section16.xml","form_type":"4"}}]}